Experimental CAR-T therapy takes aim at tough blood cancers
NCT ID NCT07200479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will also track whether the cancer shrinks or disappears, but this is a small, first-in-human study focused on safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT1194D CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so the main goal is safety, not proof of effectiveness. CAR-T therapy can cause severe side effects like cytokine release syndrome, and the cancer may still return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••